ISPOR 2022

May 15–18, 2022 | Washington, DC

Sponsor

August 2022

Carelon Research is a proud sponsor of ISPOR 2022: the leading global conference for health economics and outcomes research. Visit us at Booth #500 (or virtually), connect with our experts, and see our latest research.

Both in-person and virtual conference registration include extended access to all session playback recordings as well as virtual posters and networking through June 17, 2022. For more information, please visit ispor.org.

WORKSHOP

Concurrent breakout session 5 | Tuesday, May 17 | 1:30–2:30 pm ET

219 | Best practices for causal study designs using real-world data

Discussion leader: Michael Grabner, PhD¹

Discussants: Nilesh Gangan, PhD¹, Susan dosReis, PhD²

Learn more

¹Carelon Research, Wilmington, DE, USA
²University of Maryland School of Pharmacy, Baltimore, MD, USA

Carelon Research presentations

Carelon Research authors are indicated in bold.

Presentation	Session	Title	Authors	Affiliations
Poster Session 1 Monday, May 16 12:15 – 1:15 PM EDT	Clinical outcomes / diabetes / endocrine / metabolic disorders	CO30 \| Clinical experiences of type 2 diabetes (T2DM) patients initiating oral semaglutide	Dunn TJ¹, Swift C^1, Guesnier A¹, Noone J¹, Willey V²	¹Novo Nordisk Inc., Plainsboro, NJ, USA, ²Carelon Research, Wilmington, DE, USA
Poster Session 1 Monday, May 16 12:15 – 1:15 PM EDT	Methodological & statistical research / no additional disease & conditions / specialized treatment areas	MSR11 \| A step-by-step guide for causal study design when estimating treatment effects using real-world data	Hoffman S¹, Gangan N¹, Chen X², Smith JL¹, Tave A¹, Yang Y¹, dosReis S³, Grabner M¹	¹Carelon Research, Wilmington, DE, USA, ²Elevance Health, Indianapolis, IN, USA, ³University of Maryland School of Pharmacy, Baltimore, MD, USA
Poster Session 3 Tuesday, May 17 12:15 – 1:15 PM EDT	Clinical outcomes / diabetes / endocrine / metabolic disorders Top 5% Finalist for the ISPOR 2022 Research Presentation Awards	CO94 \| Changes in demographic and clinical characteristics of patients with type 2 diabetes (T2DM) initiating subcutaneous semaglutide	Dunn TJ¹, Swift C¹, Guesnier A¹, Noone J¹, Willey V²	¹Novo Nordisk Inc., Plainsboro, NJ, USA, ²Carelon Research, Wilmington, DE, USA
Poster Session 3 Tuesday, May 17 12:15 – 1:15 PM EDT	Economic evaluation / diabetes / endocrine / metabolic disorders	EE242 \| Economic burden among chronic kidney disease (CKD) patients with and without type 2 diabetes (T2D) in a commercially insured/Medicare advantage (MA) population in the united states (US)	Chung H¹, Thomas N¹, Willey V¹, Kong SX², Singh R², Farej R^2,, Williamson T²	¹Carelon Research, Wilmington, DE, USA, ²Bayer U.S. LLC, Whippany, NJ, USA
Poster Session 4 Tuesday, May 17 5:30 – 6:30 PM EDT	Real world data & information systems / no additional disease & conditions / specialized treatment areas	RWD106 \| Characterizing telehealth utilization from administrative claims in the US using a standardized definition	Avula R¹, Grabner M¹, Eshete B¹, Stanek E², Willey V¹	¹Carelon Research, Wilmington, DE, USA, ²Elevance Health, Inc., Indianapolis, IN, USA
Poster Session 5 Wednesday, May 18 9:00 – 10:00 AM EDT	Clinical outcomes / diabetes / endocrine / metabolic disorders Top 5% Finalist for the ISPOR 2022 Research Presentation Awards	CO158 \| A Comparison of the clinical and economic outcomes associated with short-acting bronchodilator modes of delivery among patients with chronic obstructive pulmonary disease (COPD)	Pham T¹, Chen X¹, Talavera M¹, Napier M¹, Willey V²	¹Elevance Health, Indianapolis, IN, USA, ²Carelon Research, Wilmington, DE, USA

ISPOR 2022

Sponsor

219 | Best practices for causal study designs using real-world data

Carelon Research presentations

Ready to learn more? Let's connect.